Table 2.

Overview of CDD in Myeloprotective Gene Therapy.

Model		Cell Type	Gene Expression Systems		Year	References
In vitro	Cell lines	3T3 fibroblast	Retroviral	Constitutive	1996, 1998	[24,25,28]
		CCRF-CEM (hematopoietic)	Retroviral	Constitutive	1996	[24]
		Various	Plasmid (cDNA)	Constitutive	1996	[20]
		Fibroblasts	Plasmid (cDNA)	Constitutive	1996	[23]
		NIH 3T3 fibroblast1,2	Retroviral	Constitutive	1998 to 2000	[42,43,45]
		WEHI-3 (hematopoietic)	Retroviral	Constitutive	1999	[29]
		L1210 (hematopoietic)	Retroviral	Constitutive	2001	[26]
		Human lung carcinoma cells	Retroviral	Constitutive	2002	[30]
		32D (hematopoietic)	Lentiviral (third generation)	Inducible	2012	[39]
	Primary mouse	Bone marrow cells (BMCs)	Retroviral	Constitutive	1996 to 2001	[25,26,29]
		BMCs1	Retroviral	Constitutive	1998 to 1999	[42,43]
		Bone marrow stromal cells	Retroviral	Constitutive	2002	[30]
		HSCs	Lentiviral (third generation)	Inducible	2012	[39]
	Primary human	Cord blood- and peripheral blood-derived progenitor cells	Retroviral	Constitutive	2005	[36]
In vivo	Primary mouse	Hematopoietic BMCs	Retroviral	Constitutive	1998	[27]
		BMCs1	Retroviral	Constitutive	2004	[44]
		HSCs	Retroviral	Constitutive	2006, 2012	[37,38]
		HSCs	Lentiviral (third generation)	Inducible	2012	[39]

^1,2Combinations with other CTX-R genes:

¹mutDHFR,

²glutathione S-transferase A3.